Parkinson Plus Sendromları’nın Tedavisi

Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Ahlskog JE Parkinsonism Relat Disord. 2000;7(1):63. .

Multiple system atrophy: an oligodendroglioneural synucleinopathy. Jellinger KA. J Alzheimers Dis 2018;62(3):1141-1179. doi:10.3233/JAD-170397.

. Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Lang AE, Curran T, Provias J, et al.J Neurol Sci. 1994;21(4):311 .

Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E. J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):136-40. Epub 2012 Nov 28. .

. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Bower JH, Maraganore DM, McDonnell SK, et al.Neurology. 1997;49(5):1284. .

. The natural history of multiple system atrophy: a prospective European cohort study. Wenning GK, Geser F, Krismer F, et al.Lancet Neurol. 2013 Mar;12(3):264-74. Epub 2013 Feb 5. .

. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. . Postuma RB, Iranzo A, Hogl B, et al. Ann Neurol. 2015;77(5):830. Epub 2015 Mar 13. .

. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. . Postuma RB, Iranzo A, Hogl B, et al. Ann Neurol. 2015;77(5):830. Epub 2015 Mar 13. .

First symptoms in multiple system atrophy. McKay JH, Cheshire WP. Clin Auton Res 2018; 28(2):215-221. doi:10.1007/s10286-017-0500-0.

. H. Diagnosis of multiple system atrophy. Palma JA, Norcliffe-Kaufmann L, Kaufmann Auton Neurosci 2018;211:15-25. doi:10.1016/j. autneu.2017.10.00.

. Consensus statement on the diagnosis of multiple system atrophy. Gilman S, Low PA, Quinn N, et al J Neurol Sci. 1999;163(1):94. .

. Multiple system atrophy. Wenning GK, Colosimo C, Geser F, et al..Lancet Neurol. 2004;3(2):93. .

. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Brooks DJ, Seppi K, Neuroimaging Working Group on MSA. Mov Disord. 2009;24(7):949. .

. Teaching neuroImage: MRI in multiple system atrophy: "hot cross bun" sign and hyperintense rim bordering the putamina. Massano J, Costa F, Nadais G .Neurology. 2008;71(15):e38. .

The dopaminergic response in multiple system atrophy. Hughes AJ, Colosimo C, Kleedorfer B, et al..J Neurol Neurosurg Psychiatry. 1992;55(11):1009. .

The dopaminergic response in multiple system atrophy. Hughes AJ, Colosimo C, Kleedorfer B, et al..J Neurol Neurosurg Psychiatry. 1992;55(11):1009.

Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. .Wenning GK, Ben Shlomo Y, Magalhães M, et al.Brain. 1994;117 ( Pt 4):835. .

. Multiple system atrophy. Wenning GK, Colosimo C, Geser F,et al. Lancet Neurol. 2004;3(2):93. .

. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Jain S, Dawson J, Quinn NP, et al. Mov Disord. 2004;19(11):1360.

. The influence of low-, normal-and high-carbohydrate meals on blood pressure in elderly patients with postprandial hypotension. Vloet LC, Mehagnoul-Schipper DJ, Hoefnagels WHL, et al. Gerontol A Biol Sci Med Sci 2001; 56(12):M744-M748. doi:10.1093/geron.

.. Management of multiple system atrophy: state of the art. J Neural Transm (Vienna) . Colosimo C, Tiple D, Wenning GK 2005;112(12):1695-1704. doi:10.1007/s00702-005-0379-0.

Evidence- based treatment of neurogenic orthostatic hypotension and related symptoms. . Eschlböck S, Wenning G, Fanciulli A J Neural Transm (Vienna) 2017;124(12):1567-1605. doi:10. 1007/s00702-017-1791-y.

Neuropsychiatric symptoms and their impact on quality of life in multiple system atrophy. Ceponiene R, Edland SD, Reid TN, et al. Cogent Psychol 2016; 3(1):1131476. doi:10.1080/23311908.2015.1131476.

Current concepts in the treatment of multiple system atrophy. Perez-Lloret S, Flabeau O, Fernagut PO, et al. Mov Disord Clin Pract 2015;2(1): 6-16. doi:10.1002/mdc3.12145.

. Progressıve Supranuclear Palsy. A Heterogeneous Degeneratıon Involvıng The Braın Stem, Basal Ganglıa And Cerebellum Wıth Vertıcal Gaze And Pseudobulbar Palsy, Nuchal Dystonıa And Dementıa. Steele Jc, Rıchardson Jc, Olszewskı J Arch Neurol. 1964; 10:333.

. Morning glory sign: a particular MR finding in progressive supranuclear palsy. Adachi M, Kawanami T, Ohshima H, et al. Magn Reson Med Sci. 2004;3(3):125. .

. Systematic Review of Prevalence Studies of Progressive Supranuclear Palsy and Corticobasal Syndrome. Swallow DMA, Zheng CS, Counsell CE Mov Disord Clin Pract. 2022;9(5):604. Epub 2022 Jun 28.

Milestones in atypical and secondary Parkinsonisms. Wenning GK, Litvan I, Tolosa E Mov Disord. 2011 May;26(6):1083-95. 30. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Respondek G, Kurz C, Arzberger T, Mov Disord.

. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Respondek G, Kurz C, Arzberger T, Mov Disord. 2017;32(7):995. Epub 2017 May 13. .

. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Höglinger GU, Respondek G, Stamelou M, et al.Movement Disorder Society-endorsed PSP Study Group Mov Disord. 2017;32(6):853. Epub 2017 May 3. .

. Balance and gait in progressive supranuclear palsy: a narrative review of objective metrics and exercise interventions. Dale ML, Silva-Batista C, de Almeida FO, et al.Front Neurol. 2023; 14:1212185. Epub 2023 Jun 23. .

. The ocular motor defects in progressive supranuclear palsy. Troost BT, Daroff RB Ann Neurol. 1977;2(5):397. .

Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Williams DR, de Silva R, Paviour DC, et al. Brain. 2005;128(Pt 6):1247. Epub 2005 Mar 23.

. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Boxer AL, Yu JT, Golbe LI, et al.Lancet Neurol. 2017;16(7):552. Epub 2017 Jun 13. .

. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Respondek G, Stamelou M, Kurz C, et al.Movement Disorder Society-endorsed PSP Study Group Mov Disord. 2014;29(14):1758.

. Which ante mortem clinical features predict progressive supranuclear palsy pathology? Respondek G, Kurz C, Arzberger ,et al. Movement Disorder Society-Endorsed PSP Study Group Mov Disord. 2017;32(7):995. Epub 2017 May 13. .

. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. Litvan I, Mangone CA, McKee A, et al..J Neurol Neurosurg Psychiatry. 1996;60(6):615. .

. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Boeve B, Dickson D, Duffy J, et al. Eur Neurol. 2003;49(2):72. .

Corticobasal syndrome with tau pathology. Cordato NJ, Halliday GM, McCann H, et al. Mov Disord. 2001;16(4):656. .

. Atypical progressive supranuclear palsy with corticospinal tract degeneration. Josephs KA, Katsuse O, Beccano-Kelly DA, et al.J Neuropathol Exp Neurol. 2006;65(4):396. .

. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Williams DR, Lees AJ Lancet Neurol. 2009;8(3):270. .

. Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP Centers of Care. Bluett B, Pantelyat AY, Litvan I, et al. Front Neurol 2021; 12:694872. doi:10.3389/fneur.2021.6.

. Evidence for irreversible inhibition of glycogen synthase kinase-3βby tideglusib. Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M.J Biol Chem.2012 Jan;287(2):893-904.

. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Gold M, Lorenzl S, Stewart AJ, et al. Neuropsychiatr Dis Treat. 2012; 8:85-93. Epub 2012 Feb 09. .

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Boxer AL, Lang AE, Grossman M, et al. AL-108-231 Investigators Lancet Neurol. 2014 Jul;13(7):676-85. Epub 2014 May 27.

. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. Dickson DW, Bergeron C, Chin SS, et al. J Neuropathol Exp Neurol 2002;61(11):935-946. doi:10.1093/ jnen/61.11.935 .

. Criteria for the diagnosis of corticobasal degeneration. Armstrong MJ, Litvan I, Lang AE, et al. Neurology 2013;80(5):496-503. doi:10.1212/ WNL.0b013e31827f0fd1 .

.Unusual clinical presentations of cortical-basal ganglionic degeneration. Bergeron C, Pollanen MS, Weyer L, et al. Ann Neurol 1996;40(6): 893-900. doi:10.1002/ana.410400611.

. Cortical-basal ganglionic degeneration. Riley DE Lang AE, Lewis A, et al. Black S Neurology. 1990;40(8):1203.

Criteria for the diagnosis of corticobasal degeneration. Armstrong MJ, Litvan I, Lang AE, et al. WJ Neurology. 2013;80(5):496. .

Corticobasal degeneration. Stover NP, Watts RL Semin Neurol. 2001;21(1):49. .

. Bilateral upper limb rehabilitation with videogame-based feedback in corticobasal degeneration: a case reports study. Fusco FR, Iosa M, Fusco A, et al.Neurocase. 2018;24(3):156. Epub 2018 Jul 17. .

. Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients. Shehata HS, Shalaby NM, Esmail EH, et al.Neurol Sci. 2015;36(9):1651. Epub 2015 Apr 2 .

. Clinical presentation and pharmacological therapy in corticobasal degeneration. Kompoliti K, Goetz CG, Boeve BF, et al. Arch Neurol. 1998;55(7):957. .

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by bothα-synucleinopathy and tauopathy. Moretti DV, Binetti G, Zanetti O, Frisoni GB Neuropsychiatr Dis Treat. 2014; 10:1003. Epub 2014 Jun 5.

. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Irwin DJ, Grossman M, Weintraub D, et al. Lancet Neurol 2017;16(1):55-65. doi:10.1016/S1474- 4422(16)30291-5.

. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Hu XS, Okamura N, Arai H, et al.Neurology. 2000;55(10):1575. .

Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Boeve BF, Silber MH, Ferman TJ, et al. Sleep Med. 2013;14(8):754. Epub 2013 Mar 7.

Neuropsychological deficits associated with diffuse Lewy body disease. Salmon DP, Galasko D, Hansen LA, et al. Brain Cogn. 1996;31(2):148. .

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG, Dickson DW, Lowe J, et al.Consortium on DLB Neurology. 2005;65(12):1863. Epub 2005 Oct 19. .

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. McKeith IG, Galasko D, Kosaka K, et al. Neurology. 1996;47(5):1113.

Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies. Cagnin A, Gnoato F, Jelcic N, et al. J Neurol Neurosurg Psychiatry. 2013 May;84(5):505-10. Epub 2012 Dec 21. .

. REM sleep behaviour disorder: clinical profiles and pathophysiology. Paparrigopoulos TJ Int Rev Psychiatry. 2005;17(4):293 .

. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Mega MS, Masterman DL, Benson DF, et al. Cummings JL Neurology. 1996;47(6):1403. .

. Clinical and neuropathological findings in Lewy body dementias. Galasko D, Katzman R, Salmon DP, et al.Brain Cogn. 1996;31(2):166. .

The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Vann Jones SA, O'Brien JT Psychol Med. 2014 Mar;44(4):673-83. Epub 2013 Mar 25. .

Age-associated prevalence and risk factors of Lewy body pathology in a general population: the Hisayama study. Wakisaka Y, Furuta A, Tanizaki Y, et al. Acta Neuropathol. 2003;106(4):374. Epub 2003 Aug 2. .

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Stinton C, McKeith I, Taylor JP, et al. J Psychiatry. 2015 Aug;172(8):731-42. Epub 2015 Jun 18. .

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Rolinski M, Fox C, Maidment I, et al. Cochrane Database Syst Rev. 2012; .

. A patient with probable dementia with Lewy bodies, who showed catatonia induced by donepezil: a case report]. Morita S, Miwa H, Kondo T No To Shinkei. 2004;56(10):881 .

. Improvement of both psychotic symptoms and Parkinsonism in a case of dementia with Lewy bodies by the combination therapy of risperidone and L-DOPA. Kato K, Wada T, Kawakatsu S, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(1):201. .

Autonomic dysfunctions in dementia with Lewy bodies. Horimoto Y, Matsumoto M, Akatsu H, et al. J Neurol. 2003;250(5):530. .

Autonomic dysfunction in dementia with Lewy bodies. Thaisetthawatkul P, Boeve BF, Benarroch EE, et al. Neurology. 2004;62(10):1804. .

75. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Ikeda M, Mori E, Matsuo K, et al. Alzheimers Res Ther. 2015;7(1):4. Epub 2015 Feb 3. .

. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study. Edwards K, Royall D, Hershey L, et al. Dement Geriatr Cogn Disord. 2007;23(6):401. Epub 2007 Apr 3. .

. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. McKeith I, Del Ser T, Spano P, Emre M, et al. Lancet. 2000;356(9247):2031. .

. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.Hui-Fu Wang, J.

. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. McKeith I, Fairbairn A, Perry R, et al.BMJ. 1992;305(6855.

. Olanzapine in dementia with Lewy bodies: a clinical study. Walker Z, Grace J, Overshot R, et al. Int J Geriatr Psychiatry. 1999;14(6):459.

Use of quetiapine in elderly patients. Tariot PN, Ismail MS J Clin Psychiatry. 2002;63 Suppl 13:21.

Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial. Culo S, Mulsant BH, Rosen J, et al. Alzheimer Dis Assoc Disord. 2010;24(4):360. .

Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. McGrane IR, Leung JG, St Louis EK, et al. Sleep Med. 2015;16(1):19. Epub 2014 Oct 13. .

. The Clinical Phenotype of Idiopathic Rapid Eye Movement Sleep Behavior Disorder at Presentation: A Study in 203 Consecutive Patients. Fernández-Arcos A, Iranzo A, Serradell M, et al. J Sleep. 2016;39(1):121. Epub 2016 Jan 1. .

. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Peyronnet B, Vurture G, Palma JA, et al. Parkinsonism Relat Disord. 2018; 57:22. Epub 2018 Jul 20 .

Diagnosis and differential diagnosis of Parkinson's disease and parkinsonism. Ahlskog JE Parkinsonism Relat Disord. 2000;7(1):63. .

Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. Lang AE, Curran T, Provias J, et al.J Neurol Sci. 1994;21(4):311.

Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. .Wenning GK, Ben Shlomo Y, Magalhães M, et al.Brain. 1994;117 ( Pt 4):835. .